Best Healthcare M&A Firms in the USA 2026

Healthcare M&A is its own market. Provider and payer consolidation, life sciences innovation cycles, reimbursement pressure, and regulatory scrutiny all change who the real buyers are and what they will pay for—often making healthcare deals more thesis-driven (and more diligence-heavy) than generalist processes. That’s why “best healthcare M&A firm” usually means one of two things: (1) a platform with deep healthcare buyer access across subsectors, or (2) a specialist with repeatable execution in a specific vertical (healthcare services, HCIT/digital health, medtech, biopharma). For 2026, we rank firms using a model that balances observable deal activity and third-party recognition with what matters most in practice: senior involvement and vertical pattern recognition.

Market context: 2026 dealmaking is increasingly shaped by healthcare “reinvention” themes—capabilities, data/tech enablement, and resilience—rather than simple scale alone.

Rankings Algorithm Criteria (table)

The Best Healthcare M&A Firms in the USA 2026

Important: “Total Annual Deals” is estimated for many sector boutiques because consistent public deal counts are not always disclosed. Where we use league-table deal counts, that reflects all-industry activity (not healthcare-only).

The Best Healthcare M&A Firms in the U.S., Summarized

Windsor Drake (healthtech / HCIT-adjacent niche)

Windsor Drake is best evaluated as a founder-oriented boutique that can be relevant in healthcare primarily through healthtech / HCIT-style transactions—especially when the company is still ARR-led or transitioning into predictable EBITDA. In these scenarios, “healthcare M&A” behaves more like software M&A: buyers focus on retention, gross margin durability, security/compliance posture, and the operating levers behind growth. The practical value of a boutique in this niche is disciplined positioning and diligence readiness—tight KPIs, clean data room structure, and a controlled process that prioritizes buyer quality.

• EBITDA Range: ARR-led; often pre-/low EBITDA to ~$15M+
• Total Annual Deals (Estimated): 10–25
• Principal Experience Score: 6.9 / 10
• Notable Rankings (2024–2025): Not consistently present in broad healthcare league tables; validate via deal proof + references
• Specialty: Founder-led exits; controlled sell-side prep for HCIT/healthtech

Summary of Industry Reviews (typical themes): Often chosen for senior attention and process control in founder-led settings. Validate buyer access in healthcare, healthcare-specific diligence readiness (HIPAA/security posture, customer concentration, reimbursement exposure if applicable), and negotiation ownership.

Cain Brothers (KeyBanc Capital Markets)

Cain Brothers is one of the clearest healthcare specialists for founders and executives who want an advisor that lives inside the sector—provider, payer, HCIT, and services—rather than a generalist team that “covers healthcare among many industries.” The practical benefit of that specialization is buyer realism: who is actually acquisitive, how they underwrite reimbursement exposure, what they will require in diligence, and how to structure a process that preserves confidentiality in a tightly networked market. Cain is also a frequent fit for sponsor-backed healthcare services platforms because it understands the sponsor playbook: add-ons, roll-ups, and valuation debates around quality of earnings versus growth durability.

• EBITDA Range: $5M–$150M
• Total Annual Deals (Estimated): 40–80
• Principal Experience Score: 8.7 / 10
• Notable Rankings (2024–2025): Healthcare-dedicated platform (firm-described)
• Specialty: Healthcare services + HCIT sell-side and buy-side

Summary of Industry Reviews (typical themes): Strong for healthcare pattern recognition and buyer mapping. Validate who leads negotiations at LOI and who owns the diligence cadence when buyers push for reimbursement-related protections.

Leerink Partners

Leerink is purpose-built around healthcare innovation—biopharma, medtech, diagnostics, and growth-minded healthcare companies—where EBITDA is often not the primary valuation anchor. In these deals, the advisor’s edge is less about “running an auction” and more about translating scientific/clinical value into an investable narrative: differentiated data, commercialization path, competitive landscape, and the specific buyer theses that can justify premium pricing. Leerink’s positioning as a healthcare-dedicated investment bank makes it a natural shortlist candidate for companies that need sector-native bankers rather than broad coverage.

• EBITDA Range: Pre-EBITDA to $75M+ (varies widely by subsector)
• Total Annual Deals (Estimated): 30–60
• Principal Experience Score: 8.6 / 10
• Notable Rankings (2024–2025): Healthcare-dedicated platform (firm-described)
• Specialty: Life sciences + medtech + innovation-driven healthcare

Summary of Industry Reviews (typical themes): Strong credibility with healthcare strategics and investors. Sellers should confirm the firm’s specific buyer list in your modality/subvertical and how it will manage diligence around data, regulatory pathway, and reimbursement.

Jefferies (Healthcare)

Jefferies often shows up as a pragmatic choice when a healthcare company wants broad buyer coverage and strong sponsor connectivity without losing process momentum. In healthcare services and HCIT especially, buyers can move quickly when conviction is high—and stall when the story is unclear. Jefferies is typically evaluated on its ability to create early competitive tension and keep bidders engaged through the most fragile point of the process: the handoff from IOI/indications to LOI and confirmatory diligence.

• EBITDA Range: $10M–$250M+
• Total Annual Deals (Estimated): 50–100
• Principal Experience Score: 8.4 / 10
• Notable Rankings (2024–2025): Strong Americas deal-count presence (all industries)
• Specialty: Broad healthcare coverage; sponsor + strategic outreach

Summary of Industry Reviews (typical themes): Often praised for responsiveness and execution energy. Validate senior involvement through LOI negotiation and ensure the buyer map isn’t generic—healthcare processes are won by buyer specificity.

JPMorgan (Healthcare)

JPMorgan is typically a top-tier choice for large-cap healthcare and healthcare technology mandates where complexity is high and the buyer universe can be global. The bank tends to be most valuable when the sale requires parallel workstreams—stakeholder management, regulatory sensitivity, financing considerations, and rigorous process control. Recent reporting illustrates JPMorgan’s presence in healthcare-focused mandates (e.g., advising on a potential sale of healthcare identity software firm Imprivata alongside Evercore).

• EBITDA Range: $50M+
• Total Annual Deals (Estimated): 75–150
• Principal Experience Score: 9.2 / 10
• Notable Rankings (2024–2025): Top-tier Americas deal-count presence (all industries)
• Specialty: Large healthcare/HCIT strategic processes; complex execution

Summary of Industry Reviews (typical themes): Known for handling complexity and running large processes. Sellers should lock in staffing clarity early—who drives weekly cadence, and who owns negotiation when terms get aggressive.

Goldman Sachs (Healthcare)

Goldman is a default shortlist name at the top end of healthcare M&A—especially when the mandate is board-driven, cross-border, or highly competitive. In healthcare, that often means deals where the “right” buyer is not obvious, where messaging must be precise (reimbursement exposure, regulatory timing, product roadmap), and where negotiation leverage is created through process design rather than sheer volume of outreach. Goldman also benefits from broad league-table strength by deal count (all industries), which correlates with distribution and execution scale.

• EBITDA Range: $50M+
• Total Annual Deals (Estimated): 100–200
• Principal Experience Score: 9.3 / 10
• Notable Rankings (2024–2025): #1 by Americas deal count (all industries)
• Specialty: Large-cap healthcare M&A; complex/cross-border

Summary of Industry Reviews (typical themes): Strong buyer access and negotiation posture. The diligence item is senior coverage—ensure the senior banker remains active at LOI and definitive agreement stages.

Morgan Stanley (Healthcare)

Morgan Stanley often fits healthcare mandates where strategic positioning and stakeholder management drive outcomes—particularly for large corporates, public companies, or sponsor exits with significant complexity. In healthcare, this can mean managing concentrated buyer universes, regulatory narratives, or integration logic that must be defensible to boards and investors. MS is typically judged by how well it can convert strategy into a tight buyer plan and keep the process disciplined without overexposing confidentiality.

• EBITDA Range: $50M+
• Total Annual Deals (Estimated): 70–140
• Principal Experience Score: 9.1 / 10
• Notable Rankings (2024–2025): Top-tier Americas deal-count presence (all industries)
• Specialty: Strategic healthcare M&A; board advisory

Summary of Industry Reviews (typical themes): Strong on senior advisory and positioning. Confirm diligence choreography and decision-gate discipline—healthcare timelines slip easily when Q&A is not tightly managed.

Evercore (Healthcare)

Evercore is frequently chosen when sellers want an independent advisor with strong negotiation intensity—especially when terms, certainty, and risk allocation are central. Healthcare deals often include retrade risk (reimbursement, customer concentration, clinical/regulatory, HIPAA/security posture for HCIT), and Evercore’s value shows up when the process needs to stay sharp through diligence. Reuters reporting on Imprivata’s potential sale describes Evercore assisting alongside JPMorgan, illustrating its presence in healthcare technology mandates.

• EBITDA Range: $50M+
• Total Annual Deals (Estimated): 40–90
• Principal Experience Score: 8.8 / 10
• Notable Rankings (2024–2025): Active on large healthcare/HCIT mandates (example cited)
• Specialty: Independent healthcare advisory; negotiation-heavy processes

Summary of Industry Reviews (typical themes): Strong negotiation and senior attention. Sellers should verify sector reps in their exact subvertical and how Evercore plans to defend terms (WC, earnouts, escrow, indemnity scope).

Houlihan Lokey (Healthcare)

Houlihan Lokey is often selected for middle-market healthcare processes where execution discipline matters—buyer outreach, bid comparability, and maintaining momentum through the diligence grind. Even though broad league tables are all-industry, HL’s deal-count strength signals a high-throughput execution engine—useful when a healthcare services deal needs tight sequencing and sponsor fluency.

• EBITDA Range: $5M–$150M
• Total Annual Deals (Estimated): 60–120
• Principal Experience Score: 8.3 / 10
• Notable Rankings (2024–2025): #2 by Americas deal count (all industries)
• Specialty: Middle-market healthcare; sponsor processes

Summary of Industry Reviews (typical themes): Strong process cadence. Sellers should confirm partner involvement at negotiation inflection points and ensure the buyer list is healthcare-specific, not generic sponsor outreach.

How to Choose Among Healthcare M&A Advisors

Healthcare M&A is unusually sensitive to diligence risk and deal certainty. Even strong bids can deteriorate late-stage if reimbursement exposure, billing integrity, compliance posture, or provider alignment are not framed correctly up front. The best healthcare advisors do three things exceptionally well: they target the right buyers with real conviction, they run a process that protects confidentiality and momentum, and they anticipate healthcare-specific diligence so buyers can’t weaponize it to retrade.

Start with Subsector Clarity

Healthcare is not one market. Ask every advisor to classify you precisely:

• Provider services (specialty practice, multi-site, ASC, home health, behavioral, RCM)
• Payer or managed care
• Healthcare IT or digital health
• Medtech or diagnostics
• Biopharma or life sciences
• Distribution, services, or tech-enabled healthcare

Then ask:

“What are the 3 to 5 value drivers buyers pay for in our niche right now?”

“What risks do buyers systematically haircut in this niche?”

You’re looking for answers tied to real underwriting: reimbursement durability, denial and collection efficiency, provider productivity, payer mix, referral stability, compliance readiness, and scalability, not generic “healthcare growth” statements.

Demand a Named Buyer Map with a Premium Thesis

“Show me the buyer map, with names, not categories.”

Require segmentation by strategics (with strategic logic), sponsors (with relevant platform or portfolio logic), regional versus national buyers (often decisive in provider rollups), and international buyers (usually relevant in medtech or pharma more than services).

Then ask the two questions that expose real market knowledge:

“Which 10 buyers are most likely to pay a premium, and why?”

“Which buyers will be most aggressive on terms, and why?”

In healthcare, the best advisor is often the one who knows who is active now, who has dry powder and a mandate, and who is likely to overreach on reimbursement or compliance protections.

Make Them Choose a Process Type and Defend It

Healthcare confidentiality risk is real. Leaks can spook referral sources, physician partners, employees, patients, and payer relationships.

Ask:

“Is this a broad auction, controlled auction, or targeted process?”

“How will you protect confidentiality while still creating competitive tension?”

A credible healthcare advisor should explain how they sequence outreach (who learns what, when), how they manage NDA gates and information release, how they keep two credible bidders warm through LOI, and how they control rumor risk in tight provider markets.

Validate Subsector Reps That Are Truly Comparable

“Show me 3 relevant deals from the last 24 months.”

Comparable means more than “healthcare”:

• Similar payer mix and reimbursement exposure
• Similar provider model (employed versus contracted physicians, MSO or DSO-style structures)
• Similar billing complexity (RCM intensity, coding mix, denial rates)
• Similar compliance profile (HIPAA or security, referrals or contracting practices)
• Similar buyer type (strategic versus sponsor platform or add-on)

Then ask:

“Where did diligence get contentious, and how did you prevent a retrade?”

“What terms did you defend hardest?” (working capital, escrow, earnout, special indemnities, closing conditions)

Go Deep on Healthcare Diligence Readiness

If an advisor can’t talk fluently about healthcare diligence, you’re likely to lose leverage post-LOI.

Ask:

“What will the buyer focus on in week 1 of diligence?”

“What are the top 10 diligence items we should pre-package?”

Common healthcare diligence pressure points include:

• Revenue integrity: coding and billing practices, documentation standards, denial trends, audit history
• Collections quality: net revenue yield, AR aging, bad debt, payer disputes
• Payer mix and reimbursement sensitivity: rate assumptions, policy risk, concentration
• Provider alignment and retention: productivity, contract terms, non-competes, incentives
• Compliance program maturity: training, auditing cadence, incident response
• Contracting and referral dynamics: key contracts, renewal terms, concentration dependencies
• Security and privacy posture (HCIT): audits, incidents, access controls, vendor risk

A strong advisor will propose a clear plan for Q&A triage, response time commitments, and management bandwidth protection.

Stress-Test Terms and Certainty, Not Just Headline Price

Healthcare buyers often push for protections tied to perceived risk. Ask:

“How do you defend working capital when deferred revenue or accruals are complex?”

“When do earnouts make sense in healthcare, and when do they destroy value?”

“What special indemnities do buyers typically request in our niche?”

“How do you preserve certainty of close without giving away economics?”

Listen for a focus on net proceeds and risk: escrow and indemnity structure, reps and warranties insurance posture, closing conditions and regulatory timing, termination fees and reverse break fees (larger deals).

Red Flags to Watch For

Healthcare deals blow up or get repriced for predictable reasons: reimbursement exposure, compliance risk, revenue integrity, and buyer “deal certainty” demands. If you see any of the red flags below in a pitch, treat it as a signal to dig deeper before you grant exclusivity.

• “Generic buyer list” with no subsector conviction. If the bank can’t name specific buyers and explain why they’ll pay in your niche, you’re likely getting a template process. Provider services: which strategics or sponsors have current theses in your exact specialty (GI, derm, home health, RCM)? HCIT or healthtech: which buyers underwrite ARR quality, security posture, and integration synergies, and at what multiples? Life sciences: which strategics value your modality, stage, and regulatory path? Why it matters: healthcare buyer universes are concentrated and thesis-driven; weak targeting means weak tension.
• Overpromising valuation without reimbursement underwriting. A healthcare banker who “leads with price” but can’t discuss reimbursement sensitivity is a risk. Look for fluency on payer mix and rate risk (commercial versus Medicare or Medicaid), coding and billing exposure with documentation standards, site-of-service shifts and payer policy trends, and concentration risk (top payers, top facilities, top referral sources). Why it matters: buyers price these risks through holdbacks, earnouts, special indemnities, or retrades.
• No clear plan for healthcare diligence landmines. If the bank can’t outline a diligence plan beyond “we’ll run a data room,” assume you’ll get hit with late-stage surprises. In healthcare, diligence usually zeroes in on billing integrity and collections quality, compliance program maturity (policies, training, auditing cadence), provider credentialing with licensure and sanctions screening, HIPAA or security posture (especially for HCIT), and referral relationships and contracting practices (structure and documentation). Why it matters: these issues drive deal certainty. If they surface late, buyers gain leverage.
• “We’ll figure out compliance with counsel” (the advisor abdicates). Strong advisors don’t replace lawyers, but they know enough to structure the process around healthcare reality. Red flag language includes “We don’t get involved in regulatory” or “That’s legal’s job” (without a coordinated plan). Why it matters: in healthcare, regulatory and compliance considerations affect timing, buyer appetite, and purchase agreement terms.
• Weak positioning on quality metrics and revenue integrity. Healthcare buyers pay for durable, defensible cash flows, not just growth. If the advisor doesn’t push you to present same-store trends with cohort retention (patients or customers) and utilization, clinician productivity and capacity constraints, denial rates with AR aging, bad debt, and net revenue yield, and contracting improvements with margin bridge, you’ll get repriced. Why it matters: if you can’t defend the “quality of earnings” narrative, buyers will reset expectations.

Conclusion

Healthcare M&A rewards advisors who can combine sector pattern recognition with disciplined execution—because value is won (or lost) in diligence and terms, not just in outreach. Use rankings as a starting point, then choose based on proof: recent transactions in your subsector, a buyer map that reflects who is truly acquisitive, and a concrete process plan that protects leverage through LOI, confirmatory diligence, and final documentation. In a market shaped by reinvention themes and tighter underwriting, the best healthcare M&A firm is the one that can tell your story in the language buyers pay for—and close cleanly on the terms you intended.